

***Fiscal Year 2025 Department of Defense Peer Reviewed Medical Research Program (PRMRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<b>Clinical Trial Award</b> <b>Go to:</b> <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <b>Grants.gov Funding Opportunity Number:</b> HT942525PRMRPCTA	Assistant Professor level or above (or equivalent)	<ul style="list-style-type: none"> <li>Supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of a disease or condition addressed in one of the congressionally directed FY25 PRMRP topic areas and FY25 PRMRP strategic goals.</li> <li>Proposed projects may range from small proof-of-concept trials through large-scale definitive trials.</li> <li><b><i>Submission of a Letter of Intent is required prior to full application submission.</i></b></li> <li><b><i>Clinical trials are required. Animal studies not allowed.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$8.0 million (M)</b> for total costs.</li> <li>The maximum period of performance is <b>4</b> years.</li> </ul>	<b>Pre-Application (Letter of Intent):</b> June 9, 2025 5:00 p.m. Eastern time  <b>Application:</b> July 21, 2025 11:59 p.m. Eastern time
<b>Technology/Therapeutic Development Award</b> <b>Go to:</b> <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <b>Grants.gov Funding Opportunity Number:</b> HT942525PRMRPTTDA	Assistant Professor level or above (or equivalent)	<ul style="list-style-type: none"> <li>Supports the translation of promising preclinical findings into products for clinical applications including prevention, detection, diagnosis, treatment, and/or quality of life for a disease or condition related to one of the FY25 PRMRP topic areas and one of the FY25 PRMRP strategic goals.</li> <li>Supports product-oriented projects (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.</li> <li><b><i>Submission of a Letter of Intent is required prior to full application submission.</i></b></li> <li><b><i>Clinical trials are not allowed.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>The maximum allowable funding for the entire period of performance is <b>\$3.5M</b> for total costs.</li> <li>The maximum period of performance is <b>4</b> years.</li> </ul>	<b>Pre-Application (Letter of Intent):</b> June 9, 2025 5:00 p.m. Eastern time  <b>Application:</b> July 21, 2025 11:59 p.m. Eastern time